We characterized the clinical relevance of CTGF in breast tumor progression, and the results revealed that high expression of CTGF in tumor cells but not in stroma cells significantly correlated with poor clinical prognosis and outcomes in breast tumors. This evidence concerns the gene CCN2 and neoplasm.